About Translyx
Auckland-based clinical technology holding entity — the governed evidence layer for clinical AI in New Zealand and Oceania.
Our mission
Translyx Limited brings advanced diagnostic and clinical products to the New Zealand healthcare sector — giving clinicians and health services access to technologies that improve diagnostic accuracy, clinical decision-making, and patient outcomes.
The team combines deep expertise across diagnostics, laboratory medicine, clinical implementation, and healthcare supply. That experience informs how Translyx selects, evaluates, and introduces globally validated innovations — matching the right technology to the right clinical environment, across hospital, community, and research settings.
Translyx approaches product introduction at the system level. Diagnostic capability is not an isolated procurement decision — it shapes how clinicians make decisions, how labs operate, and how patients experience care.
Leadership
Dr Ehsan Ullah
Founding Director
Translyx Ltd was established in December 2025 by Dr Ehsan Ullah, an Auckland-based physician scientist and healthcare entrepreneur advancing clinical diagnostic solutions in New Zealand.
Globally, the diagnostic market is undergoing rapid transformation driven by emerging trends in antimicrobial resistance (AMR), sepsis diagnostics, point-of-care testing, endocrinology, cardiac markers, artificial intelligence, and precision medicine. These advances are reshaping clinical decision-making and patient outcomes, creating a clear and urgent need for experienced leadership to bring advanced diagnostic technologies onshore to meet local healthcare demands.
Dr Ullah brings an established professional profile at the intersection of clinical practice, laboratory medicine, and health technology innovation — including leadership roles across specialised diagnostics and digital health initiatives. His vision for Translyx is grounded in translating cutting-edge global diagnostic innovations into practical, high-impact solutions for the New Zealand healthcare system.
The Translyx senior leadership team includes healthcare professionals with over 50 years of collective experience across the in vitro diagnostics (IVD) market, pathology services, and next-generation molecular diagnostic solutions. The team is committed to building strategic partnerships and expanding access to high-quality, clinically meaningful diagnostic tools.
Translyx Ltd represents Dr Ullah's commitment to strengthening diagnostic capability in Aotearoa New Zealand — supporting clinicians, laboratories, and healthcare providers with advanced solutions that improve patient care and system resilience.
Operational territory
Translyx operates primarily in New Zealand, with planned expansion into Australia and the broader Oceania region, including selected Pacific Island markets. The company works closely with local laboratories, hospitals, and healthcare providers to ensure diagnostic solutions are relevant, practical, and aligned with real clinical needs. Through regional partnerships and scalable distribution models, Translyx aims to strengthen diagnostic capability across Oceania while enabling efficient market access for international diagnostic innovators.
Primary
- New Zealand — national
Expanding
- Australia
- Pacific Island markets
Partner model
- Local labs and hospitals
- Academic research centres
- Manufacturer partnerships
Work with Translyx
Speak with the team about diagnostic product evaluation, Privexa Trace workflows, or the broader Translyx portfolio.